Karyopharm Therapeutics Inc. (KPTI)
| Market Cap | 161.02M +183.0% |
| Revenue (ttm) | 151.12M +6.3% |
| Net Income | -194.97M |
| EPS | -14.19 |
| Shares Out | 22.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 571,964 |
| Open | 7.66 |
| Previous Close | 7.67 |
| Day's Range | 7.08 - 8.04 |
| 52-Week Range | 3.65 - 10.99 |
| Beta | 0.81 |
| Analysts | Buy |
| Price Target | 13.50 (+89.08%) |
| Earnings Date | May 14, 2026 |
About KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom... [Read more]
Financial Performance
In 2025, Karyopharm Therapeutics's revenue was $146.07 million, an increase of 0.57% compared to the previous year's $145.24 million. Losses were -$196.04 million, 156.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for KPTI stock is "Buy." The 12-month stock price target is $13.5, which is an increase of 89.08% from the latest price.
News
Karyopharm reports Q1 EPS ($1.24), consensus ($1.44)
Reports Q1 revenue $35.1M, consensus $31.4M. “As we move through 2026, Karyopharm (KPTI) is in a pivotal period with meaningful clinical and regulatory milestones ahead,” said CEO Richard Paulson. “Th...
Karyopharm sees 2026 revenue $130M-$150M, consensus $137.49M
07:33 EDT Karyopharm (KPTI) sees 2026 revenue $130M-$150M, consensus $137.49M
Karyopharm Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue growth, key clinical milestones in myelofibrosis and endometrial cancer, and improved operating discipline. SENTRY trial results were compelling, and the company is well-funded for upcoming catalysts, reaffirming 2026 guidance.
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
– Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expected Mid-2026 – – Phase 3 SENTRY Results Selected for Late-Breaking Oral Presentation at ASCO on June 2 – –...
Karyopharm to Participate at Upcoming Investor Conferences
NEWTON, Mass., May 12, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's...
Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026
-- Conference Call Scheduled for Thursday, May 14, 2026, at 8:00 a.m. ET -- NEWTON, Mass.
Karyopharm price target raised to $13 from $8 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Karyopharm (KPTI) to $13 from $8 and keeps a Buy rating on the shares. The firm sees a greater probability of approval…
Karyopharm files $400M mixed securities shelf
16:38 EDT Karyopharm (KPTI) files $400M mixed securities shelf
Karyopharm files to sell 8.84M shares of common stock for holders
16:39 EDT Karyopharm (KPTI) files to sell 8.84M shares of common stock for holders
Karyopharm price target raised to $16 from $8 at Piper Sandler
Piper Sandler raised the firm’s price target on Karyopharm (KPTI) to $16 from $8 and keeps an Overweight rating on the shares. The firm notes Karyopharm will report Phase III…
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
NEWTON, Mass., April 21, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its late-br...
Karyopharm price target lowered to $16 from $23 at RBC Capital
RBC Capital lowered the firm’s price target on Karyopharm (KPTI) to $16 from $23 and keeps an Outperform rating on the shares as part of the firm’s broader research note…
Karyopharm price target lowered to $8 from $12 at Piper Sandler
Piper Sandler lowered the firm’s price target on Karyopharm (KPTI) to $8 from $12 and keeps an Overweight rating on the shares. Phase III SENTRY data in myelofibrosis met the…
Karyopharm price target lowered to $15 from $21 at Baird
Baird lowered the firm’s price target on Karyopharm (KPTI) to $15 from $21 and keeps an Outperform rating on the shares. The firm updated its model following mixed Ph 3…
Karyopharm price target lowered to $8 from $15 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Karyopharm (KPTI) to $8 from $15 and keeps a Buy rating on the shares. Following the most recently reported clinical results, the…
Karyopharm Therapeutics Transcript: Study result
The phase III SENTRY trial showed Selinexor plus Ruxolitinib nearly doubled spleen response rates and provided a significant overall survival benefit in JAK inhibitor-naive Myelofibrosis, with a manageable safety profile and evidence of disease modification.
Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study
Karyopharm Therapeutics said on Tuesday its oncology therapy showed a statistically significant improvement in spleen volume in a late‑stage trial in patients with a rare blood cancer, one of...
Karyopharm’s Phase 3 SENTRY trial meets first co-primary endpoint
Karyopharm (KPTI) Therapeutics reported topline results from its Phase 3 SENTRY trial, a randomized, double-blind, placebo-controlled trial of 60 mg selinexor in combination with ruxolitinib in frontl...
Karyopharm announces $30M private placement
Karyopharm (KPTI) Therapeutics announced that it has entered into a securities purchase agreement with RA Capital Management for a private placement that is expected to result in gross proceeds of…
Karyopharm Announces $30 Million Private Placement with RA Capital
NEWTON, Mass., March 24, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has ente...
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
– While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS – – SENTRY Demonstrated a Rapid and Near Doubli...
Karyopharm initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Karyopharm (KPTI) with a Buy rating and $28 price target The firm is positive on selinexor’s “differentiated” mechanism of action and “compelling” Phase 1…
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., March 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company ...
Karyopharm Therapeutics Transcript: EGM 2026
A virtual special meeting was held to vote on increasing authorized shares and the potential adjournment for further proxy solicitation. Both proposals passed, with final results to be filed in a Form 8-K. No questions were raised by stockholders.
Karyopharm Therapeutics Earnings Call Transcript: Q4 2025
Revenue grew modestly in 2025, with XPOVIO sales up and cost reductions improving operating loss. Pivotal phase 3 data in myelofibrosis is expected in March, with a strong commercial focus on this opportunity and a cash runway into Q2 2026.